Internal Medicine, Hematology & Oncology · Tuscaloosa, AL
NPI
1164666483
Since 2009
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
1410 McFarland Blvd N
Tuscaloosa, AL, 35406
Phone (205) 345-8208
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.0M
97,514 services
Medicare patients, 2024
276
Average age 73
Drug cost, 2024
$8.5M
1,978 prescriptions
Company payments, 2025
$1,068
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alejandro Garcia was code J0897 (injection, denosumab, 1 mg), 8,700 times for 36 patients. In total Alejandro Garcia billed 97,514 services in 114 codes, and Medicare paid $1.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-04-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,700 | 36 | $13.32 | $116K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,692 | 19 | $0.07 | $125 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,204 | 22 | $0.09 | $109 |
| 96367 Intravenous Infusion, Hydration | Office | 475 | 26 | $19.84 | $9,425 |
| 96372 Injection Administration | Office | 301 | 52 | $9.59 | $2,885 |
| 99213 Office E&M - Established | Office | 291 | 168 | $59.41 | $17K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 195 | 19 | $34.80 | $6,787 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 188 | 49 | $45.26 | $8,510 |
| 99214 Office E&M - Established | Office | 169 | 93 | $85.12 | $14K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 141 | 26 | $0.64 | $89.98 |
| 96413 Chemotherapy Administration | Office | 111 | 16 | $88.93 | $9,871 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 86 | 15 | $0.00 | $0.15 |
| 96365 Intravenous Infusion, Hydration | Office | 71 | 23 | $40.40 | $2,868 |
| 99215 Office E&M - Established | Office | 68 | 39 | $113.04 | $7,687 |
| 99457 E&M - Miscellaneous | Office | 63 | 11 | $35.33 | $2,226 |
By year: 2022 $942K for 70,835 services; 2023 $832K for 78,223 services; 2024 $1.0M for 97,514 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 31 | 28 | $7.41 | $230 |
| 36415 Venipuncture Blood Collection | 25 | 23 | $8.65 | $216 |
| 80053 Clinical Chemistry | 18 | 17 | $10.35 | $186 |
Medicare prescription drug claims, 2024
In 2024, the drug Alejandro Garcia prescribed most often to Medicare patients was Letrozole, with 336 prescriptions and refills. In total Alejandro Garcia wrote 1,978 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 336 | 647 | 79 | $6,909 |
| Tamoxifen Citrate Generic | 87 | 129 | 13 | $2,089 |
| Xtandi Enzalutamide | 81 | 81 | 13 | $1.1M |
| Anastrozole Generic | 74 | 126 | 20 | $1,085 |
| Prolia Denosumab | 72 | 432 | 46 | $121K |
| Xgeva Denosumab | 66 | 66 | Under 11 | $208K |
| Procrit Epoetin Alfa | 49 | 49 | 14 | $134K |
| Erleada Apalutamide | 44 | 44 | Under 11 | $583K |
| Keytruda Pembrolizumab | 43 | 43 | Under 11 | $475K |
| Trazimera Trastuzumab-Qyyp | 41 | 41 | Under 11 | $218K |
| Dexamethasone Generic | 41 | 47 | 13 | $769 |
| Imbruvica Ibrutinib | 40 | 40 | Under 11 | $489K |
| Ondansetron Hcl Generic | 38 | 38 | 23 | $1,173 |
| Neulasta Onpro Pegfilgrastim | 36 | 36 | Under 11 | $251K |
| Venlafaxine Hcl Er Venlafaxine Hcl | 33 | 69 | 13 | $331 |
Brand drugs: 861 claims; generic drugs: 1,117 claims; opioid claims: 22.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alejandro Garcia $1,068 ($1,068 in general payments such as food, travel and fees) from 18 companies. The largest payer was Novartis Pharmaceuticals Corporation with $209.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 8 | $209 |
| Pfizer Inc. PFE | 10 | $155 |
| Array Biopharma Inc PFE | 4 | $113 |
| TerSera Therapeutics LLC | 4 | $88.14 |
| Daiichi Sankyo Inc. 4568.T | 4 | $74.64 |
| Merck Sharp & Dohme LLC MRK | 3 | $69.95 |
| Dendreon Pharmaceuticals LLC | 2 | $56.09 |
| Celgene Corporation BMY | 2 | $50.76 |
| Stemline Therapeutics Inc. | 2 | $39.36 |
| Coherus Oncology, Inc. CHRS | 2 | $34.26 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.